drugset / Trial / NCT07712913

Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia

NCT07712913

Phase 3 Recruiting 348 enrolled Brainfarma
RandomizedParallel-groupDouble-blindTreatment

Summary

Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia

Timeline

Start
2026-06-18
Primary completion
2027-06-01
Completion
2027-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 300 mg
Subject Pregabalin Small molecule 660 mg